We are presenting a poster at the ESMO Breast Cancer Annual Congress (#ESMOBreast23) from 11-13 May in Berlin. The poster demonstrates that the Digistain Prognostic Score showed high accuracy and predictive performance, and stratified patients with early breast cancer into low or high risk. The low cost, rapidity and accessibility of Digistain’s technology approach has potential as an alternative or addition to existing prognostic tools across real-life clinical practice, including under-resourced settings.
Digistain Launches First International Lab in South Africa
In our ongoing effort to bring accessible cancer diagnostics to the regions that need them most, we are proud to announce the official launch of
